| アブストラクト | JAVEMACS-D was an observational, retrospective study describing real-world characteristics, treatment patterns, and outcomes in patients with advanced urothelial carcinoma (aUC) treated with avelumab maintenance after first-line platinum-based chemotherapy (PBC) in Japan using a large claims database (Medical Data Vision). Between February 2021 and April 2023, 773 patients received avelumab maintenance; median age was 74 years, primary tumor site was bladder in 59.9% and renal pelvis/ureter in 42.7%, and first-line PBC was cisplatin-gemcitabine in 61.3% and carboplatin-gemcitabine in 36.4%. Avelumab maintenance started in 2021 in 289 patients (37.4%) and in 2022 or later in 484 (62.6%). At data cutoff (October 2023), median follow-up was 19.3 months, and 22.0% of patients were still receiving avelumab. Among 394 patients (51.0%) who received second-line treatment, the most common was enfortumab vedotin (EV) in 47.0%. Median time to treatment failure (TTF; time from start of avelumab maintenance to discontinuation) was 4.5 months (95% CI 3.8-5.2). Median TTF2 (time from start of avelumab to discontinuation of subsequent treatment) was 10.1 months (95% CI 8.7-11.0). JAVEMACS-D represents the largest real-world dataset of avelumab maintenance therapy for aUC reported to date. Data provide insights about patient characteristics, treatment patterns, and outcomes within an evolving treatment landscape. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2025/11/26 |
|---|
| 投稿者 | Kobayashi, Takashi; Kitamura, Hiroshi; Furukawa, Yuka; Shono, Michihiro; Ito, Takayuki; Kikuchi, Eiji |
|---|
| 組織名 | Department of Urology, Kyoto University Graduate School of Medicine, Kyoto,;Japan. selecao@kuhp.kyoto-u.ac.jp.;Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.;Clinical Research Department, Ark Medical Solutions Inc., Tokyo, Japan.;Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of;Merck KGaA, Tokyo, Japan.;Department of Urology, St Marianna University School of Medicine, Kanagawa,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41290744/ |
|---|
